NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES
QUEBEC CITY, Dec. 8, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Corporation") (TSXV: OPS) (OTCQX: OPSSF)
is pleased to announce that it has closed its previously announced
short form prospectus financing (the "Offering") through a
syndicate of agents led by Paradigm Capital Inc. and including RBC
Capital Markets and M Partners Inc. (collectively, the "Agents").
The Corporation issued 8,667,000 Common Shares (the "Common
Shares"), at a price of $1.50 per
Common Share for gross proceeds of $13,000,500. The Agents also exercised their
over-allotment option (the "Over-Allotment Option") to acquire an
additional 1,300,000 Common Shares for additional gross proceeds of
$1,950,000. Including the proceeds
from the exercise of the Over-Allotment Option, the total gross
proceeds of the Offering were $14,950,500, with a total of 9,967,000 Common
Shares being issued. The Agents received a cash fee equal to 6% of
the gross proceeds of the Offering, excluding Common Shares sold to
certain president's list subscribers, for which the Agents received
a cash fee equal to 3%.
The Corporation intends to use the net proceeds of the Offering
to execute the commercialization and marketing strategy of its
Fractional Flow Reserve products ("FFR"), to fund research and
product development and to fund its working capital.
This press release does not constitute an offer of securities
for sale in the United States or to "U.S. persons" ("U.S.
persons"), as such term is defined in Regulation S promulgated
under the United States Securities Act of 1933, as amended (the
"U.S. Securities Act"). The securities being offered have not been,
nor will be, registered under the U.S. Securities Act or any state
securities laws, and may not be offered or sold in the United
States or to U.S. persons absent registration or an applicable
exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Corporation develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other
demanding industrial applications.
Except for historical information, this press release may
contain "forward-looking statements" and "forward-looking
information" within the meaning of applicable securities laws that
reflect Opsens' current expectation regarding future events,
including, without limitation the use of the net proceeds of the
Offering. Forward-looking statements contained in this press
release involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance and achievements
of Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements. Opsens expressly disclaims any
intention to update or revise any forward-looking statements and
information whether as a result of new information, future events
or otherwise, other than as required by law.
Neither TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this release.
SOURCE OPSENS INC.